Sickle Cell Disease

The FDA announced several regulatory actions the past few weeks.

Sickle cell disease is known to be associated with severe pain, but the current care model primarily focuses on acute vaso-occlusive pain.

Treatment with exagamglogene autotemcel conferred clinically meaningful increases in fetal hemoglobin and total hemoglobin levels among patients with beta-thalassemia and sickle cell disease, results of two pivotal studies showed.

Unemployment, depression, female sex and older age appeared associated with increased pain frequency among patients with sickle cell disease, according to study results published in JAMA Network Open.

An analysis of individuals in the United States with public insurance showed that those with sickle cell disease died more than 20 years earlier than the average person.

Massage therapy can benefit young patients with cancer or hematologic conditions, according to retrospective study results.

Fewer than 4% of eligible individuals with sickle cell disease received prescriptions for newer FDA-approved pain medications, according to study results published in Blood Advances.

Odds of several adverse pregnancy outcomes appeared strikingly similar between pregnant people with anemia and pregnant people with sickle cell disease, according to a study published in JAMA Network Open.

Keith Hoots, MD, received ASH’s Outstanding Service Award.

ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.